LYSAKER, Norway, May 8, 2016 (GLOBE NEWSWIRE) —
BioEquity
Targovax announces that Gunnar Gårdemyr, Chief Executive Officer, will hold a presentation at BioEquity Europe in Copenhagen, Denmark on Wednesday, May 11, 2016.
The presentation will be available the same day at Targovax’s website http://www.targovax.com/investors/presentations
Invitation to presentation of first quarter 2016 results
Targovax will release its Q1 2016 results on Thursday, May 12, 2016 at 07:00 CET. The quarterly report and the presentation material will be available at this time at www.targovax.com.
At 14:30 CET (08:30 EST) Targovax will host a telephone conference, including a presentation of the results, followed by a Q&A session. Call-in details can be found below and on the Targovax website.
Make sure to dial-in at least 5-10 minutes ahead to complete your registration.
Participant information:
Call-in numbers:
Norway Toll-Free Number: 800 19 747
Norway Toll Number: +47 23 50 05 59
UK Toll-Free Number: 080 823 700 30
UK Toll Number: +44 203 139 4830
US Toll-Free Number: 1866 928 7517
US Toll Number: +1 718 873 9077
See attached list for more call – in numbers.
http://wpc.1726.planetstream.net/001726/FEL_Events_International_Access_List.pdf
Access code:
14438925#
About Targovax: “Arming the patient’s immune system to fight cancer”
Targovax is a clinical stage immuno-oncology company developing targeted immunotherapy treatments for cancer patients. Targovax has a broad and diversified immune therapy portfolio and aims to become a leader in its area. The company is currently developing two complementary and highly targeted approaches in immuno-oncology.
ONCOS – 102 is a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes targeting solid tumors. This treatment is designed to reactivate the immune system’s capacity to recognize and attack cancer cells.
TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the difficult to treat RAS mutations found in more than 85% of pancreatic cancers, 50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards demonstrating that TG vaccines will prolong time to cancer progression and increase survival.
These product candidates will be developed in combination with multiple treatments in several cancer indications, including checkpoint inhibitors. Targovax also has a number of other cancer immune therapy candidates in the early stages of development. For more information go to www.targovax.com.
For further information, please contact:
Gunnar Gårdemyr
CEO
Phone: +41 798 340 585
Email: ggardemyr@targovax.com
Øystein Soug
CFO
Phone: +47 906 56 525
Email: oystein.soug@targovax.com
HUG#2010304
